Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2014 3
2015 6
2016 5
2017 3
2018 3
2019 3
2021 4
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells.
Saleiro D, Kosciuczuk EM, Fischietti M, Perez RE, Yang GS, Eckerdt F, Beauchamp EM, Hou Y, Wang Q, Weinberg RS, Fish EN, Yue F, Hoffman R, Platanias LC. Saleiro D, et al. Cancer Res Commun. 2023 May 31;3(5):943-951. doi: 10.1158/2767-9764.CRC-23-0010. eCollection 2023 May. Cancer Res Commun. 2023. PMID: 37377894 Free PMC article.
Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors.
Fenton SE, Zannikou M, Ilut L, Fischietti M, Ji C, Oku CV, Horvath CM, Le Poole IC, Bosenberg M, Bartom ET, Kocherginsky M, Platanias LC, Saleiro D. Fenton SE, et al. Among authors: saleiro d. Mol Cancer Res. 2023 Apr 1;21(4):332-344. doi: 10.1158/1541-7786.MCR-22-0684. Mol Cancer Res. 2023. PMID: 36573964 Free PMC article.
Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms.
Saleiro D, Wen JQ, Kosciuczuk EM, Eckerdt F, Beauchamp EM, Oku CV, Blyth GT, Fischietti M, Ilut L, Colamonici M, Palivos W, Atsaves PA, Tan D, Kocherginsky M, Weinberg RS, Fish EN, Crispino JD, Hoffman R, Platanias LC. Saleiro D, et al. Nat Commun. 2022 Apr 1;13(1):1750. doi: 10.1038/s41467-022-29381-7. Nat Commun. 2022. PMID: 35365653 Free PMC article.
ULK1 in type I interferon response.
Saleiro D, Platanias LC. Saleiro D, et al. Oncotarget. 2015 Sep 22;6(28):24586-7. doi: 10.18632/oncotarget.5241. Oncotarget. 2015. PMID: 26309084 Free PMC article. No abstract available.
Type I and II Interferons in the Anti-Tumor Immune Response.
Fenton SE, Saleiro D, Platanias LC. Fenton SE, et al. Among authors: saleiro d. Cancers (Basel). 2021 Mar 2;13(5):1037. doi: 10.3390/cancers13051037. Cancers (Basel). 2021. PMID: 33801234 Free PMC article. Review.
Intersection of mTOR and STAT signaling in immunity.
Saleiro D, Platanias LC. Saleiro D, et al. Trends Immunol. 2015 Jan;36(1):21-9. doi: 10.1016/j.it.2014.10.006. Epub 2014 Nov 15. Trends Immunol. 2015. PMID: 25592035 Free PMC article. Review.
Targeting novel signaling pathways for resistant acute myeloid leukemia.
Sakamoto KM, Grant S, Saleiro D, Crispino JD, Hijiya N, Giles F, Platanias L, Eklund EA. Sakamoto KM, et al. Among authors: saleiro d. Mol Genet Metab. 2015 Mar;114(3):397-402. doi: 10.1016/j.ymgme.2014.11.017. Epub 2014 Dec 5. Mol Genet Metab. 2015. PMID: 25533111 Free PMC article. Review.
30 results